Oct 10 (Reuters) - CAMP4 Therapeutics, a
biopharmaceutical firm backed by healthcare giant Kaiser
Permanente on Thursday raised $75 million after pricing its U.S.
initial public offering (IPO).
CAMP4 sold 6.82 million shares in the IPO for $11 per share,
the company said in a statement.
(Reporting by Pretish M J in Bengaluru)